X0609 4 2026-06-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001853327 Burrows Scott L false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer 1 Common Stock 2026-06-01 4 M 0 7500 14.50 A 105494 D Common Stock 2026-06-01 4 S 0 1801 69.75 D 103693 D Common Stock 2026-06-01 4 S 0 2599 70.77 D 101094 D Common Stock 2026-06-01 4 S 0 3100 72.06 D 97994 D Stock Option (Right to Buy) 14.50 2026-06-01 4 M 0 7500 0 D 2033-09-01 Common Stock 7500 374857 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-06-03